Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients
NCT00551655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 684
Last updated 2007-11-06
Summary
Tenofovir (TDF)-containing regimens may be associated with decreasing renal function in HIV-infected patients concurrently treated with boosted PI's and/or have co-morbid conditions including diabetes mellitus, hypertension, anemia, hepatitis B, and hepatitis C.
Conditions
- Human Immunodeficiency Viruses
- Kidney Failure
- HIV Infections
Sponsors & Collaborators
- collaborator INDUSTRY
-
AIDS Arms Inc.
lead OTHER
Principal Investigators
-
Keith Rawlings, MD · AIDS Arms Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Completion
- 2007-09-30
Countries
- United States
Study Locations
More Related Trials
-
Kidney Transplant for HIV-Infected Patients in Renal Failure
NCT00009009 ·Status: COMPLETED ·Phase: PHASE2
-
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
NCT00106379 ·Status: COMPLETED ·Phase: PHASE4
-
TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment
NCT04391608 ·Status: UNKNOWN ·Phase: PHASE4
-
Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies
NCT02209740 ·Status: COMPLETED
-
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
NCT04993872 ·Status: UNKNOWN ·Phase: PHASE4
-
TAF for HIV-HBV With Renal Dysfunction
NCT03115736 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
NCT02246998 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
NCT03284164 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
NCT02269917 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902 ·Status: COMPLETED ·Phase: PHASE3
-
Emtricitabine/Tenofovir Alafenamide as Salvage ART
NCT02556333 ·Status: TERMINATED ·Phase: PHASE2
-
The Lighthouse Tenofovir Cohort Study
NCT02381275 ·Status: UNKNOWN
-
Renal Integrase Study
NCT02351908 ·Status: COMPLETED ·Phase: PHASE4
-
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
NCT01906255 ·Status: COMPLETED
-
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
NCT02674581 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease
NCT02487706 ·Status: COMPLETED ·Phase: PHASE4
-
Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen
NCT03646370 ·Status: COMPLETED
-
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
NCT02600819 ·Status: COMPLETED ·Phase: PHASE3
-
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055 ·Status: COMPLETED ·Phase: PHASE4
-
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
NCT05652478 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
NCT06101342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy
NCT04448158 ·Status: COMPLETED
-
A Comparison of Two Anti-HIV Treatment Plans
NCT00005915 ·Status: COMPLETED
-
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
NCT01818596 ·Status: COMPLETED ·Phase: PHASE3